Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT04722146
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 350
- Registration Number
- NCT04678089
- Locations
- 🇨🇳
Beijng Chao Yang Hospital, Beijing, China
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 45
- Registration Number
- NCT04626791
- Locations
- 🇺🇸
Ochsner NCI Community Oncology Research Program, New Orleans, Louisiana, United States
🇺🇸Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT04570631
- Locations
- 🇫🇷
CHRU Lille - Hopital Claude Huriez /ID# 222302, Lille, Nord, France
🇫🇷Institut Gustave Roussy /ID# 223951, Villejuif Cedex, Val-de-Marne, France
🇺🇸Norton Healthcare Pavilion /ID# 222918, Louisville, Kentucky, United States
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 1450
- Registration Number
- NCT04566328
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 357
- Registration Number
- NCT04484623
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04474938
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04433156
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 141
- Registration Number
- NCT04414475
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇬🇷Theageneion Cancer Hospital, Thessaloniki, Greece
🇮🇱Rabin Medical Center (Beilinson Hospital), Petah Tikva, Israel
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT04392648
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.